Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial

Status Completed

Clinical Trial Summary

This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Assess the activity of bevacizumab, in terms of 6-month progression-free survival rate and objective tumor response, in patients with recurrent or persistent endometrial cancer.

II. Determine the nature and degree of toxicity of bevacizumab in these patients.

SECONDARY OBJECTIVES:

I. Determine the duration of progression-free survival and overall survival of these patients.

II. Determine the effects of prognostic factors, including performance status and histological grade.

OUTLINE:

Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00301964
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	March 2006
Completion date	July 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03968406` - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Phase 1
Active, not recruiting	`NCT03508570` - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Phase 1
Completed	`NCT00723255` - Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00025467` - Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Active, not recruiting	`NCT03120624` - VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	Phase 1
Recruiting	`NCT05691504` - Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Phase 1
Active, not recruiting	`NCT04781088` - Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01764789` - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer	N/A
Recruiting	`NCT04469764` - Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Phase 2
Terminated	`NCT03924245` - Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Phase 1
Completed	`NCT00462826` - VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00096447` - Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00028535` - Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors	Phase 1
Completed	`NCT01652794` - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	Phase 1
Completed	`NCT01079832` - Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Phase 2
Completed	`NCT00095979` - Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00072176` - Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Phase 2
Withdrawn	`NCT01943058` - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT03914612` - Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	Phase 3

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms